Angiotensin-converting enzyme inhibitor in a human model of restenosis

  • G. R. Heyndrickx

Abstract

Percutaneous transluminal coronary angioplasty (PTCA) was introduces by Andreas Gruentzig in 1977, as an alternative treatment for coronary artery bypass grafting (CABG) to restore coronary blood flow in patients with obstructive coronary artery disease (15). Increased experience and advances in technology have resulted in a high primary success rate (over 90%) and a low compilation rate (death, non-fatal myocardial infarction; 4–5%) (9). However, the late restenosis rate (17% to 40%) still limits the long-term benefit of the procedure (21, 23, 47, 52).

Keywords

Aspirin Angiotensin Coumadin Cardiol Verapamil 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V (1985) Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 5: 609–616PubMedCrossRefGoogle Scholar
  2. 2.
    Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleveland JP, Kussmaul WG, Hirshfeld JW (1987) Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76: 125–134PubMedCrossRefGoogle Scholar
  3. 3.
    Bilazarian SD, Currier JW, Haudenschild C, Hey man D, Powell J, Ryan TJ, Faxon DP (1991) Angiotensin converting enzyme inhibition reduces restenosis in experimental angioplasty [abstract]. J Am Coll Cardiol 17: 2: 268ACrossRefGoogle Scholar
  4. 4.
    Burnier M, Mooser V, Nussberger J, Waeber B, Brunner HR (1989) Correlation between plasma concentration of Cilazapril and hemodynamic and hormonal effects in healthy man. Br J Clin Pharmac 27: 189S–197SGoogle Scholar
  5. 5.
    Califf RM, Ohman EM, Frid DJ, Fortin DF, Mark DB, Hlatky MS, Herndon JE, Bengtson JR (1990) Restenosis: The clinical issues, in Topol EJ (ed): Textbook of Interventional Cardiology. Philadelphia, WB Saunders Co, 63: 394Google Scholar
  6. 6.
    Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Shum L, Tim- mermans PBMWH, Brunner HR (1991) Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 83: 1333–1342Google Scholar
  7. 7.
    Churchill DA, Siegel CO, Dougherety KG, Raizner A, Minor ST (1991) Failure of enalapril to reduce coronary restenosis in a swine model (abstract). Circulation 84: 4: 11–297Google Scholar
  8. 8.
    Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM (1991) Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68: 450–456PubMedGoogle Scholar
  9. 9.
    Detre K, Holubkov R, Kelsey S, Cowley M, Kent K, Williams D, Myler R, Faxon D, Holmes D Jr, Bourassa M, Block P, Gosselin A, Bentivoglio L, Leatherman L, Dorros G, King S III, Galichia J, Al-Bassam M, Leon M, Robertson T, Passamani E, Co-Investigators of the NHLBI PTCA Registry (1988) Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981. The National Heart Lung Blood Institute Registry. N Engl J Med 318: 265–270Google Scholar
  10. 10.
    Dorros G, Cowley MJ, Simpson J, Bentifoglio LG, Block PC, Bourassa M, Detre K, Gosselin AJ, Gruentzig AR, Kelsey SF, Kent KM, Mock MB, Mullins SM, Myler RK, Passamani ER, Stertzer SH, Williams DO (1983) Percutaneous transluminal coronary angioplasty: Report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. Circulation 67: 4: 723–730PubMedCrossRefGoogle Scholar
  11. 11.
    Fingerle J, Au YPT, Clowes AW, Reidy MA (1990) Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Atheriosclerosis 10: 1082–1087Google Scholar
  12. 12.
    Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA (1989) Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci 86: 8412–8416PubMedCrossRefGoogle Scholar
  13. 13.
    Flemming RM, Kirkeeide RL, Smalling RW, Gould KL, Stuart Y (1991) Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography. J Am Coll Cardiol 18: 945–951CrossRefGoogle Scholar
  14. 14.
    Forrester JS, Fishbein M, Helfant R, Fagin J (1991) A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17: 758–769PubMedCrossRefGoogle Scholar
  15. 15.
    Gruentzig AR, Senning A, Siegenthaler WE (1979) Nonoperative dilatation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 301: 61-68Google Scholar
  16. 16.
    Hammacher A, Hellman U, Johnsson A, Östman A, Gunnarsson K, Westermark, B, Wasteson Ä, Heldin CH (1988) A major part of platelet-derived growth factor purified from human platelets is a heteromer of one A and one B chain. J Biol Chem 263: 16493 - 16498PubMedGoogle Scholar
  17. 17.
    Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, Harker LA (1991) Effects of angiotensin-converting enzyme inhibition with Cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 18 (suppl H): 70–76Google Scholar
  18. 18.
    Hermans WRM, Rensing BJ, Strauss BH, Serruys PW (1991) Prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA): The search for a “magic bullet”. Am Heart J 122: 1: 171–187PubMedCrossRefGoogle Scholar
  19. 19.
    Huber KC, Schwartz RS, Edwards WD, Camrud AR, Murphy JG, Jorgenson M, Holmes DR (1991) Restenosis and angiotensin-converting enzyme inhibition: effects on neointimal proliferation in a porcine coronary injury model (abstract). Circulation 84: 4: 11–298Google Scholar
  20. 20.
    Jawien A, Lindner V, Bowen-Pope DF, Schwartz SM, Reidy MA, Clowes AW (1990) Platelet derived growth factor ( PDGF) stimulates arterial smooth muscle cell proliferation in vivo (abstract ). FASEB 4: 342Google Scholar
  21. 21.
    Kaltenbach M, Kober G, Scherer D, Vallbracht C (1985) Recurrence rate after successful angioplasty. Eur Heart J 6: 276–281PubMedGoogle Scholar
  22. 22.
    Lam JYT, Bourassa MG, Blaine L, Lachapelle C (1990) Can Cilazapril reduce the development of atherosclerotic changes in the balloon injured porcine carotid arteries? (abstract). Circulation 82: 4: 111–429Google Scholar
  23. 23.
    Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, King III SB, Gruentzig AR (1986) Restenosis after successful angioplasty in patients with single-vessel disease. Circulation 73: 710–717PubMedCrossRefGoogle Scholar
  24. 24.
    Lindner V, Reidy MA (1991) Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci 88: 3739–3743PubMedCrossRefGoogle Scholar
  25. 25.
    Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA (1991) Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 68: 106–113PubMedGoogle Scholar
  26. 26.
    Liu MW, Roubin GS, King SB (1989) Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 79: 1374–1387Google Scholar
  27. 27.
    Mabin TA, Holmes DR Jr, Smith HC, Vlietstra RE, Bove AA, Reeder GS, Chesebro JH, Bresnahan JF, Orszulak TA (1985) Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 5: 198–202Google Scholar
  28. 28.
    Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM (1990) PDGF ligand and receptor gene expression during repair ligand. J Cell Biol 111: 2149–2158PubMedCrossRefGoogle Scholar
  29. 29.
    Naftilan AJ, Pratt RE, Dzau VJ (1989) Induction of platelet derived growth factor A chain and C-myc gene expressions by angiotensin II in culture rat vascular smooth muscle cells. J Clin Invest 83: 1419–1424PubMedCrossRefGoogle Scholar
  30. 30.
    Nussberger J, Brunner DB, Waeber B, Brunner HR (1985) True versus immunoreactive angiotensin II in human plasma. Hypertension 7 (suppl I):l–17Google Scholar
  31. 31.
    Owens GK, Schwartz SM (1983) Vascular smooth muscle cell hypertrophy and hyperploidy in the Goldblatt hypertensive rat. Cir Res 53: 491–500Google Scholar
  32. 32.
    Owens GK, Reidy MA (1985) Hyperplastic growth response of vascular smooth muscle cells following induction of acute hypertension in rats by aortic coarctation. Cir Res 57: 659–670Google Scholar
  33. 33.
    Owens GK (1987) Influences of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 9: 178–187PubMedGoogle Scholar
  34. 34.
    Powell JS, Clozel JP, Müller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR (1989) Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186–188PubMedCrossRefGoogle Scholar
  35. 35.
    Powell JS, Muller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR (1990) The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacology 16 (suppl 4): S42–S49CrossRefGoogle Scholar
  36. 36.
    Powell JS, Rouge M, Muller RK, Baumgartner HR (1991) Cilazapril suppresses myointimal proliferation after vascular injury: effects on growth factor induction and vascular smooth muscle cells. Basic Research in Cardiology 86 (suppl I): 65–74PubMedGoogle Scholar
  37. 37.
    Rakugi H, Krieger J, Wang DS, Dzau VJ, Pratt RE (1991) Induction of angiotensin converting enzyme in neointima after balloon injury (abstract). Circulation 84: 4: 11–113Google Scholar
  38. 38.
    Reiber JHC, Serruys PW, Kooyman CJ, Wijns W, Slager CJ, Gerbrands M, Schuurbiers JCH, den Boer A, Hugenholtz PG (1985) Assessment of short, medium and long term variations in arterial dimensions from computer assisted quantification of coronary cineangiograms. Circulation 71: 280–288PubMedCrossRefGoogle Scholar
  39. 39.
    Reiber JHC, Serruys PW (1990) Quantitative coronary angiography, in Marcus ML, Schelbert HR, Skorton DJ, Wolf GL (ed): Cardiac Imaging: A Companion to Braunwald’s Heart Disease. Philadelphia, WB Saunders Co, pp 211–280Google Scholar
  40. 40.
    Rensing BJ, Hermans WRM, Deckers JW, de Feyter PJ, Tijssen JGP, Serruys PW (1992) Luminal narrowing after percutaneous transluminal coronary balloon angioplasty follows a near gaussian distribution. A quantitative angiographic study in 1445 successfully dilated lesions. J Am Coll Cardiol 9: 939–945Google Scholar
  41. 41.
    Ross R (1986) The pathogenesis of atherosclerosis. An update. N Engl J Med 314: 488–500PubMedCrossRefGoogle Scholar
  42. 42.
    Sahni R, Maniet AR, Voci G, Banka VS (1991) Prevention of restenosis by lovastatin after successful angioplasty. Am Heart J 121: 1600–1608PubMedCrossRefGoogle Scholar
  43. 43.
    Schwartz SM, Campbell GR, Campbell JH (1986) Replication of smooth muscle cells in vascular disease. Circ Res 58: 427–444PubMedGoogle Scholar
  44. 44.
    Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR (1988) Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318: 1714–1719PubMedCrossRefGoogle Scholar
  45. 45.
    Schwartz RS, Huber KC, Edwards WD, Camrud AR, Jorgenson M, Holmes DR (1991) Coronary restenosis and the importance of mural thrombus: results in a porcine coronary model (abstract). Circulation 84: 4: 11–71Google Scholar
  46. 46.
    Scott-Burden T, Resink TJ, Hahn AWA, Bühler FR (1990) Induction of thrombospondin expression in vascular smooth muscle cells by angiotensin II. J Cardiovasc Pharm 16 (suppl 7): 17–20Google Scholar
  47. 47.
    Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JHC, Ten Katen HJ, van Es GA, Hugenholtz PG (1988) Incidence of restenosis after successful coronary angioplasty: a time related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3 and 4 months. Circulation 77: 361–371Google Scholar
  48. 48.
    Serruys PW, Rensing BJ, Luijten HE, Hermans WRM, Beatt KJ (1990) Restenosis following coronary angioplasty. In Meier B (ed) Interventional Cardiology. Bern: Hogrefe and Huber Publishers, 79: 115Google Scholar
  49. 49.
    Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast G, Wijns W, Rensing BJ, Vos J, Stibbe J (1991) for the CARPORT study group. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2 receptor blockade. A randomized, double blind, placebo controlled trial. Circulation 84: 1568–1580Google Scholar
  50. 50.
    Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, Fuster V (1985) Balloon angioplasty: Natural history of the pathophysiological response to injury in the pig model. Cir Res 57: 105–112Google Scholar
  51. 51.
    The Multicenter European Research Trial with Cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis (Mercator) study Group (1992) Circulation 86: 100–110Google Scholar
  52. 52.
    Vandormael MG, Deligonul U, Kern M, Harper M, Presant S, Gibson P, Galan K, Chaitman BR (1987) Multilesion coronary angioplasty: clinical and angiographic follow- up. J Am Coll Cardiol 10: 246–252PubMedCrossRefGoogle Scholar
  53. 53.
    Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP (1987) Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 75: 636–642PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1993

Authors and Affiliations

  • G. R. Heyndrickx
    • 1
  1. 1.Cardiovascular CenterOnze Lieve Vrouw ZiekenhuisAalstBelgium

Personalised recommendations